Thursday, November 01, 2018 6:13:17 PM
The FDA could easily say, "yeah we might accept this, BUT we need a little more data first, can you give us some more statistics from patients in 6 months first please" and then like that HSGX has to reverse split to keep from being delisted, do another offering and dilute to raise more money. I mean it could get really ugly real quick.
The news for now is still fairly neutral. Just trying to be honest and explain for everyone reading this that this is far from a sure thing. Could still totally get approved for a BLA filing, but maybe in 6 months. Thing is, no one knows for sure for another month now.
Recent OCGN News
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 05/10/2024 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:14:11 PM
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock • GlobeNewswire Inc. • 05/10/2024 08:05:06 PM
- Ocugen to Present at May 2024 Investor Conferences • GlobeNewswire Inc. • 05/10/2024 11:45:07 AM
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/03/2024 11:30:05 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress • GlobeNewswire Inc. • 05/02/2024 11:15:46 AM
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 • GlobeNewswire Inc. • 04/29/2024 10:45:00 AM
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 01:05:24 PM
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 10:30:40 AM
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy • GlobeNewswire Inc. • 04/19/2024 11:13:05 AM
- Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets • GlobeNewswire Inc. • 04/12/2024 11:30:34 AM
- Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 04/10/2024 11:02:26 AM
- Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 04/08/2024 10:30:43 AM
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy • GlobeNewswire Inc. • 04/05/2024 11:02:21 AM
- Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 • GlobeNewswire Inc. • 04/02/2024 12:00:39 PM
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 04/01/2024 10:08:46 PM
- Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 • GlobeNewswire Inc. • 04/01/2024 09:43:45 PM
- Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 10:30:50 AM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 • GlobeNewswire Inc. • 03/13/2024 12:00:54 PM
- Ocugen to Present at Investing in Cures Summit • GlobeNewswire Inc. • 03/06/2024 12:30:09 PM
- Ocugen Clinical Showcase Webcast Now Available • GlobeNewswire Inc. • 02/28/2024 01:00:26 PM
- Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit • GlobeNewswire Inc. • 02/26/2024 01:30:13 PM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Ocugen to Present at 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 04:22:29 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM